KEGG   COMPOUND: C00355
Entry
C00355                      Compound                               
Name
3,4-Dihydroxy-L-phenylalanine;
L-Dopa;
3-Hydroxy-L-tyrosine;
L-beta-(3,4-Dihydroxyphenyl)alanine;
Levodopa;
Dihydroxy-L-phenylalanine
Formula
C9H11NO4
Exact mass
197.0688
Mol weight
197.1879
Structure
Remark
Same as: D00059
Reaction
Pathway
map00350  Tyrosine metabolism
map00950  Isoquinoline alkaloid biosynthesis
map00965  Betalain biosynthesis
map01060  Biosynthesis of plant secondary metabolites
map01063  Biosynthesis of alkaloids derived from shikimate pathway
map01100  Metabolic pathways
map01110  Biosynthesis of secondary metabolites
map04728  Dopaminergic synapse
map04917  Prolactin signaling pathway
map05012  Parkinson disease
map05030  Cocaine addiction
map05031  Amphetamine addiction
map05034  Alcoholism
Module
M00042  Catecholamine biosynthesis, tyrosine => dopamine => noradrenaline => adrenaline
M00961  Betacyanin biosynthesis, L-tyrosine => amaranthin
Network
nt06028  Dopamine and serotonin metabolism
nt06463  Parkinson disease
Enzyme
1.10.3.1        1.11.2.6        1.13.11.29      1.13.11.30      
1.13.11.-       1.13.12.15      1.14.16.2       1.14.18.1       
1.14.-.-        2.6.1.49        4.1.1.25        4.1.1.28        
4.1.1.107       4.3.1.22
Brite
Compounds with biological roles [BR:br08001]
 Peptides
  Amino acids
   Other amino acids
    C00355  3,4-Dihydroxy-L-phenylalanine
 Hormones and transmitters
  Neurotransmitters
   Amino acids
    C00355  Dopa
Prodrugs [br08324.html]
 C00355
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 N NERVOUS SYSTEM
  N04 ANTI-PARKINSON DRUGS
   N04B DOPAMINERGIC AGENTS
    N04BA Dopa and dopa derivatives
     N04BA01 Levodopa
      D00059  Levodopa (JP18/USP/INN) <JP/US>
USP drug classification [BR:br08302]
 Antiparkinson Agents
  Dopamine Precursors and/or L-Amino Acid Decarboxylase Inhibitors
   Levodopa
    D00059  Levodopa (JP18/USP/INN)
Therapeutic category of drugs in Japan [BR:br08301]
 1  Agents affecting nervous system and sensory organs
  11  Agents affecting central nervous system
   116  Antiparkinsonian agents
    1164  Levodopas
     D00059  Levodopa (JP18/USP/INN)
Drug groups [BR:br08330]
 Neuropsychiatric agent
  DG01472  Dopamine agonist
   D00059  Levodopa
  DG01967  Antiparkinson agent
   D00059  Levodopa
Drug classes [BR:br08332]
 Neuropsychiatric agent
  DG01967  Antiparkinson agent
   D00059  Levodopa
Target-based classification of drugs [BR:br08310]
 G Protein-coupled receptors
  Rhodopsin family
   Dopamine
    DRD
     D00059  Levodopa (JP18/USP/INN) <JP/US>
Drugs listed in the Japanese Pharmacopoeia [BR:br08311]
 Chemicals
  D00059  Levodopa
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D00059
Prodrugs [br08324.html]
 D00059
Other DBs
CAS: 59-92-7
PubChem: 3648
ChEBI: 15765
KNApSAcK: C00001357
PDB-CCD: DAH[PDBj]
3DMET: B01224
NIKKAJI: J9.225H
LinkDB
KCF data

ATOM        14
            1   C8y C    22.9600  -19.2500
            2   C8y C    22.9600  -20.6500
            3   C8x C    24.1500  -18.5500
            4   O1a O    21.7000  -18.5500
            5   C8x C    24.1500  -21.3500
            6   O1a O    21.7000  -21.3500
            7   C8y C    25.3400  -19.2500
            8   C8x C    25.3400  -20.6500
            9   C1b C    26.6000  -18.6200
            10  C1c C    27.7900  -19.2500
            11  C6a C    28.9800  -18.6200
            12  N1a N    27.7900  -20.6500
            13  O6a O    30.2400  -19.2500
            14  O6a O    28.9800  -17.2200
BOND        14
            1     1   2 1
            2     1   3 2
            3     1   4 1
            4     2   5 2
            5     2   6 1
            6     3   7 1
            7     5   8 1
            8     7   9 1
            9     9  10 1
            10   10  11 1
            11   10  12 1 #Up
            12   11  13 1
            13   11  14 2
            14    7   8 2

» Japanese version

DBGET integrated database retrieval system